Both nivolumab and pembrolizumab can be considered as options in high risk for relapse resected melanoma—IIIA–IIIC pembrolizumab, IIIB–IV nivolumab—regardless of BRAF status (level of evidence 1, grade of recommendation A). Here, BRAF is linked to melanoma.